Medical Aesthetics
Medical aesthetics is the $22 billion U.S. category covering elective, primarily cosmetic, minimally invasive and non-invasive procedures performed by board-certified dermatologists, plastic surgeons, and aesthetic medical practitioners. The category spans neurotoxins (Botox, Dysport, Jeuveau), dermal fillers (Juvéderm, Restylane, Belotero, RHA), energy-based body contouring (CoolSculpting, EmSculpt, Sofwave), skin tightening and resurfacing (Morpheus8, Thermage, Ultherapy), medical-grade skincare (SkinCeuticals, SkinMedica, Obagi), and surgical aesthetic procedures.
The category compounded through aging-demographic demand, normalization of preventive aesthetics, and integration into broader luxury and wellness brand portfolios. As of 2026, medical aesthetics is the fastest-shifting healthcare sub-category in AI citation behavior. GLP-1 demand is remaking patient demand patterns. Traditional social-media referral via Instagram and TikTok is collapsing as the first stop for patient research, replaced by AI engines.
The 5W and Haute MD Medical Aesthetics AI Visibility Index 2026 is the first published ranking of the category by AI citation share. Botox, Juvéderm, CoolSculpting, SkinCeuticals, and Morpheus8 lead; the top 15 brands capture 62% of category citation share.